Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years of age or older
- You have been diagnosed with a gynecologic cancer (such as ovarian, cervical, or uterine cancer) or breast cancer
- You are about to start your first cycle of certain chemotherapy treatment plans involving paclitaxel, with or without other chemotherapy drugs (confirm specific regimen details with trial site)
- You are receiving your cancer treatment at the main Dana-Farber Cancer Institute (DFCI) campus locations (currently Yawkey 9 and 10, or Chestnut Hill)
- You are able to fill out questionnaires written in English or Spanish
Who may not be able to join:
- You have previously received chemotherapy that is known to cause nerve damage
- You already have nerve damage or a nerve condition (such as numbness or tingling) before starting this trial
- You have a history of certain blood or circulation conditions, including Raynaud's phenomenon, cold agglutinin disease, cryoglobulinemia, cryofibrinogenemia, post-traumatic cold dystrophy, peripheral arterial ischemia, or sickle cell disease (confirm with trial site)
- You are currently going through a desensitization treatment process (confirm with trial site)
- You have lymphedema (swelling caused by fluid buildup) in the arm or leg where the trial device would be placed
- You have open skin wounds or sores on the arms or legs where the trial device would be placed
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Theresa Jabaley Leonarczyk, PhD, RN, Dana-Farber Cancer Institute
Phone: 617-582-8037
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Patient-Reported CIPN Symptoms Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy module at End of Treatment; Duration of Cryocompression Tolerated During Neurotoxic Chemotherapy; Incidence of Core Temperature Decrease >1°F and Skin Intolerance Symptoms Associated with Cryocompression
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.